Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14696607 | 0.84 | L3MBTL1 (0.53) | ALDH1A1L3MBTL1PKMTAAR1LMNA | |
| SCHEMBL19406117 | 0.82 | L3MBTL1 (0.46) | ALDH1A1L3MBTL1PKMTAAR1LMNA | |
| SCHEMBL21198513 | 0.81 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1PKMTAAR1LMNA | |
| SCHEMBL9810683 | 0.81 | L3MBTL1 (0.54) | ALDH1A1L3MBTL1PKMTAAR1MAPT | |
| SCHEMBL16896797 | 0.81 | L3MBTL1 (0.54) | ALDH1A1L3MBTL1PKMTAAR1LMNA | |
| SCHEMBL27343291 | 0.81 | L3MBTL1 (0.50) | ALDH1A1L3MBTL1PKMTAAR1MAPT | |
| SCHEMBL24728704 | 0.80 | L3MBTL1 (0.47) | ALDH1A1L3MBTL1PKMTAAR1MAPT | |
| SCHEMBL1396121 | 0.80 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1PKMTAAR1MAPT | |
| SCHEMBL9730065 | 0.80 | L3MBTL1 (0.44) | ALDH1A1L3MBTL1PKMTAAR1LMNA | |
| SCHEMBL19698979 | 0.79 | L3MBTL1 (0.59) | ALDH1A1L3MBTL1PKMTAAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111218005-A | Preparation method of nitroimidazole-polyoxometallate copper complex and application of nitroimidazole-polyoxometallate copper complex in electrochemical energy storage aspect | 南京农业大学 | 2020-06-02 | — | — | CN | claimed |
| CN-117777196-B | Method for synthesizing Ai Fulin amide isomer derivative | 常州大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-117777196-A | Method for synthesizing Ai Fulin amide isomer derivative | 常州大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-111218005-A | Preparation method of nitroimidazole-polyoxometallate copper complex and application of nitroimidazole-polyoxometallate copper complex in electrochemical energy storage aspect | 南京农业大学 | 2020-06-02 | — | — | CN | disclosed |
| US-10174067-B2 | Type of cytidine derivative and application thereof | CHANGZHOU FANGYUAN PHARMACEUTICAL CO., LTD (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20170355726-A1 | NEW TYPE OF CYTIDINE DERIVATIVE AND APPLICATION THEREOF | CHANGZHOU FANGYUAN PHARMACEUTICAL CO., LTD (CN) | 2017-12-14 | — | — | US | disclosed |
| US-20170355726-A1 | NEW TYPE OF CYTIDINE DERIVATIVE AND APPLICATION THEREOF | CHANGZHOU FANGYUAN PHARMACEUTICAL CO., LTD (CN) | 2017-12-14 | — | — | US | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617266-B2 | Imidazopyrimidine derivatives | MERCK PATENT GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| EP-2964648-B1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2016-11-16 | — | — | EP | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| EP-2663553-B1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORP (US) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014135245-A1 | 9-(ARYL OR HETEROARYL)-2-(PYRAZOLYL, PYRROLIDINYL OR CYCLOPENTYL)AMINOPURINE DERIVATIVES AS ANTICANCER AGENTS | MERCK PATENT GMBH (DE) | 2014-09-12 | — | — | WO | disclosed |
| EP-2663553-A2 | QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2012030944-A2 | QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| CN-102119157-A | Tricyclic 2,4-diamino-L,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders | ASTRAZENECA AB | 2011-07-06 | — | — | CN | disclosed |
| US-7589207-B2 | Cyclohexyl compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296363-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS | JAK3, JAK2, JAK1 | ALDH1A1 4518/4885L3MBTL1 2847/4885PKM 1334/4885 |
| US-20160002242-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | EIF2AK4, GCN1, EIF4A2 | ALDH1A1 2452/4885L3MBTL1 571/4885PKM 2521/4885 |
| US-10174067-B2 | Type of cytidine derivative and application thereof | DCTD, TYMP, RNMT | ALDH1A1 1109/4885L3MBTL1 1345/4885PKM 4161/4885 |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | THPO, MPL, MCL1 | ALDH1A1 855/4885L3MBTL1 3406/4885PKM 2762/4885 |
| US-20170355726-A1 | NEW TYPE OF CYTIDINE DERIVATIVE AND APPLICATION THEREOF | DCTD, RNMT, TYMP | ALDH1A1 1450/4885L3MBTL1 1667/4885PKM 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.